Pesquisadores of Universidade Estadual Paulista found that women with breast cancer who took a daily vitamin D supplement had a 79% higher treatment success rate than those who did not take the nutrient. The study, carried out at Faculdade of Medicina of Botucatu and financed by Fundação of Amparo to Pesquisa of Estado of São Paulo (FAPESP), followed 80 women undergoing neoadjuvant chemotherapy. The results were published in the scientific journal Nutrition and Cancer and suggest that a simple and accessible approach can transform responses to cancer treatment.
The research represents a significant advance in chemotherapy enhancement strategies. Vitamin D, an essential nutrient also for calcium absorption and immune health, has been shown to be capable of amplifying the effectiveness of conventional treatment. The finding gains special relevance considering the reduced cost of the supplement compared to similar medications developed for the same purpose, many of which are not part of the Sistema Único and Saúde portfolio.
Resultados that surprise researchers
Of the women who received a daily dose of 2,000 international units (IU) of vitamin D, 43% had complete disappearance of their cancer after chemotherapy. In the placebo group, only 24% achieved complete remission. The difference of 19 percentage points consolidates the scientists’ hypothesis that the nutrient works as a silent chemotherapy enhancer. Eduardo Carvalho-Pessoa, president of Sociedade Brasileira of Mastologia of Região of São Paulo and one of the authors of the study, highlights the magnitude of the result.
“Even with a small sample of participants, it was possible to observe a significant difference in the response to chemotherapy”, says Carvalho-Pessoa. The dosage used in the research remains considerably below the recommended limit for correcting deficiency. Enquanto the study used 2,000 IU daily, the conventional protocol to restore adequate levels recommends 50,000 IU weekly. Esse fact intensifies the value of the discovery: powerful results with minimal amounts of the supplement.
Todas participants were over 45 years old and received care at the oncology outpatient clinic of Hospital of Clínicas at FMB-UNESP. The women were divided into two groups with balanced distribution, ensuring methodological rigor. The research followed each participant during six months of neoadjuvant treatment, a protocol administered before surgery to reduce tumors and facilitate removal.
The broad role of vitamin D in the body
Vitamin D transcends its classic function of assisting in the absorption of calcium and phosphorus, critical nutrients for bone maintenance. Evidências Growing scientific evidence demonstrates a crucial role in immune function, enabling the body to defend itself against infections and chronic diseases, including neoplasms. The immune system strengthened by vitamin D apparently recognizes and fights cancer cells more efficiently when associated with conventional chemotherapy.
Muitos Previous studies that investigated vitamin D and cancer focused on dosages much higher than those used in this research. The new work opens up a different perspective by demonstrating effectiveness with reduced quantities. Esse finding simplifies clinical implementation and reduces risks of toxicity due to excess vitamin D, an adverse effect documented at very high doses.
The body synthesizes vitamin D mainly through exposure to ultraviolet solar radiation. Alimentos such as fatty fish, egg yolks and fortified dairy products complement this endogenous production. International nutritional guidelines recommend a minimum intake of 600 IU daily for adults and 800 IU for the elderly. Academia Americana of Pediatria recommends 400 IU daily for babies. Essas quantities guarantee adequate blood levels without risk of toxicity. Excessive Ingestão causes uncomfortable symptoms:
- Náuseas and persistent vomiting
- Fraqueza muscle and fatigue
- Dor generalized bone
- Formação of kidney stones
- Hipercalcemia with cardiac complications
Deficiência widespread among cancer patients
At the beginning of follow-up, the overwhelming majority of participants had insufficient levels of vitamin D, defined as less than 20 nanograms per milliliter (ng/mL) of blood. Sociedade Brasileira of Reumatologia recommends maintaining blood levels between 40 and 70 ng/mL for optimal health. Essa basal deficiency represents an aggravating factor in the oncological context, compromising the immunological response already weakened by the neoplasm and its aggressive treatment.
With systematic supplementation during the six months of chemotherapy, vitamin D levels progressively increased in members of the intervention group. Essa gradual recovery of circulating levels correlated with better therapeutic responses. Carvalho-Pessoa explains the mechanism: “With supplementation, levels increased throughout chemotherapy treatment, which reinforces a possible contribution to patients’ recovery.” Restoration of adequate levels allowed the immune system to function at maximum potential, synchronized with chemical aggression against tumor cells.
Acessibilidade versus conventional medicines
Vitamin D emerges as a noticeably more accessible option compared to other medications developed for a similar purpose. Alguns immunopotentiating agents cost thousands of reais per treatment cycle and are often not included in the list of medications offered by Sistema Único and Saúde. Low-income Pacientes face insurmountable financial barriers to accessing conventional complementary therapies.
Vitamin D supplements cost a fraction of the price of these sophisticated medications. A box with 30 tablets of 2,000 IU costs approximately 30 to 50 reais in Brazilian pharmacies. Essa economic viability opens up extraordinary possibilities to expand access to enhancing therapeutic strategies in health systems with restricted budgets. Carvalho-Pessoa emphasizes this advantage: “Vitamin D is an accessible and cheap option compared to other medications used to improve the response to chemotherapy, some of which are not even on the SUS list.”
Limitações and future paths
The researchers recognize that the sample of 80 women, although demonstrating a statistically significant difference, remains too small for definitive conclusions. Further Estudos with hundreds of participants will validate preliminary findings and clarify biological mechanisms by which vitamin D enhances chemotherapy. Será needs to be investigated whether the benefit applies to other types of cancer in addition to breast cancer or whether it presents limitations to specific subtypes of breast tumors.
Teams continue to monitor participants to assess long-term effects, disease recurrence and overall survival. Esses clinical endpoints will complement the initial pathological response documented in the present study. Carvalho-Pessoa concludes with tempered optimism: “These are encouraging results that justify a new round of studies with a larger number of participants. Isso will allow a better understanding of the role of vitamin D in increasing the response to chemotherapy treatment and, consequently, in the greater likelihood of breast cancer remission.”